{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:24:15Z","timestamp":1785781455219,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Self-help Program of Natural Science Foundation of Heilongjiang Province","award":["LH2024H071"],"award-info":[{"award-number":["LH2024H071"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-01895-2","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T02:28:16Z","timestamp":1754533696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin targeted the immune-related gene PIK3CA in type 2 diabetes mellitus treatment: network pharmacology analysis and experimental evidence"],"prefix":"10.1186","volume":"17","author":[{"given":"Heng","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Man","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Hong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","first-page":"109911","DOI":"10.1016\/j.abb.2024.109911","volume":"753","author":"A Akhter","year":"2024","unstructured":"Akhter A, Alouffi S, Shahab U, Akasha R, Fazal-Ur-Rehman M, Ghoniem ME, et al. Vitamin D supplementation modulates glycated hemoglobin (HBA1c) in diabetes mellitus. Arch Biochem Biophys. 2024;753:109911.","journal-title":"Arch Biochem Biophys"},{"key":"1895_CR2","doi-asserted-by":"publisher","first-page":"108796","DOI":"10.1016\/j.biopha.2019.108796","volume":"114","author":"S Hu","year":"2019","unstructured":"Hu S, Wang R, Zhang M, Liu K, Tao J, Tai Y, et al. BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway. Biomed Pharmacother. 2019;114:108796.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1895_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","volume":"50","author":"MG Tinajero","year":"2021","unstructured":"Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: A global perspective. Endocrinol Metab Clin North Am. 2021;50(3):337\u201355.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"1895_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S2213-8587(14)70161-5","volume":"2","author":"EW Gregg","year":"2014","unstructured":"Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KM, Thompson TJ. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985\u20132011: a modelling study. Lancet Diabetes Endocrinol. 2014;2(11):867\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1895_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1758-5996-5-57","volume":"5","author":"L Litwak","year":"2013","unstructured":"Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013;5(1):57.","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"1895_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S2213-8587(16)30010-9","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Gregg EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol. 2016;4(6):537\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1895_CR7","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/db20-0084","volume":"69","author":"S Yuan","year":"2020","unstructured":"Yuan S, Kar S, Carter P, Vithayathil M, Mason AM, Burgess S, et al. Is type 2 diabetes causally associated with cancer risk?? Evidence from a Two-Sample Mendelian randomization study. Diabetes. 2020;69(7):1588\u201396.","journal-title":"Diabetes"},{"issue":"3","key":"1895_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14740338.2016.1135900","volume":"15","author":"IJ Neeland","year":"2016","unstructured":"Neeland IJ, Salahuddin U, McGuire DK. A safety evaluation of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Saf. 2016;15(3):393\u2013402.","journal-title":"Expert Opin Drug Saf"},{"key":"1895_CR9","first-page":"104555","volume":"81","author":"A Shafiq","year":"2022","unstructured":"Shafiq A, Mahboob E, Samad MA, Ur Rehman MH, Tharwani ZH. The dual role of empagliflozin: cardio renal protection in T2DM patients. Ann Med Surg (Lond). 2022;81:104555.","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"1895_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13098-022-00951-5","volume":"14","author":"S Gohari","year":"2022","unstructured":"Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, et al. The effect of empagliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and coronary artery disease: the EMPA-CARD randomized controlled trial. Diabetol Metab Syndr. 2022;14(1):170.","journal-title":"Diabetol Metab Syndr"},{"key":"1895_CR11","doi-asserted-by":"crossref","unstructured":"Iannantuoni F, Diaz-Morales AMM, Falcon N, Banuls R, Abad-Jimenez C. Z, The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. 2019;8(11).","DOI":"10.3390\/jcm8111814"},{"issue":"1","key":"1895_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41574-021-00575-1","volume":"18","author":"S SantaCruz-Calvo","year":"2022","unstructured":"SantaCruz-Calvo S, Bharath L, Pugh G, SantaCruz-Calvo L, Lenin RR, Lutshumba J, et al. Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities. Nat Rev Endocrinol. 2022;18(1):23\u201342.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1895_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nri.2016.40","volume":"16","author":"A Mehta","year":"2016","unstructured":"Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16(5):279\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"1895_CR14","doi-asserted-by":"publisher","first-page":"10908","DOI":"10.7150\/thno.48264","volume":"10","author":"C Zhang","year":"2020","unstructured":"Zhang C, Han X, Yang L, Fu J, Sun C, Huang S, et al. Circular RNA circPPM1F modulates M1 macrophage activation and pancreatic islet inflammation in type 1 diabetes mellitus. Theranostics. 2020;10(24):10908\u201324.","journal-title":"Theranostics"},{"issue":"2","key":"1895_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.7150\/thno.29678","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, et al. Circular RNAs in immune responses and immune diseases. Theranostics. 2019;9(2):588\u2013607.","journal-title":"Theranostics"},{"key":"1895_CR16","doi-asserted-by":"crossref","unstructured":"Song G, Zhang Y, Jiang Y, Zhang H, Gu W, Xu X et al. Circular RNA PIP5K1A promotes glucose and lipid metabolism disorders and inflammation in type 2 diabetes mellitus. Mol Biotechnol. 2024;66(12):3549-58.","DOI":"10.1007\/s12033-023-00954-1"},{"key":"1895_CR17","doi-asserted-by":"publisher","first-page":"9920744","DOI":"10.1155\/2022\/9920744","volume":"2022","author":"J Zhou","year":"2022","unstructured":"Zhou J, Zhang X, Ji L, Jiang G. Identification of potential biomarkers of type 2 diabetes Mellitus-Related immune infiltration using weighted gene coexpression network analysis. Biomed Res Int. 2022;2022:9920744.","journal-title":"Biomed Res Int"},{"issue":"1","key":"1895_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, et al. Molecular and Pharmacological modulators of the tumor immune contexture revealed by Deconvolution of RNA-seq data. Genome Med. 2019;11(1):34.","journal-title":"Genome Med"},{"key":"1895_CR19","doi-asserted-by":"crossref","unstructured":"Xie R, Li B, Jia L, Li Y. Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci. 2022;23(2):794.","DOI":"10.3390\/ijms23020794"},{"issue":"1","key":"1895_CR20","doi-asserted-by":"publisher","first-page":"9569","DOI":"10.1038\/s41598-023-36687-z","volume":"13","author":"M Hu","year":"2023","unstructured":"Hu M, Yan H, Li H, Feng Y, Sun W, Ren Y, et al. Use of network Pharmacology and molecular Docking to explore the mechanism of action of curcuma in the treatment of osteosarcoma. Sci Rep. 2023;13(1):9569.","journal-title":"Sci Rep"},{"key":"1895_CR21","volume-title":"StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Vivek podder declares no relevant financial relationships with ineligible companies","author":"O Sizar","year":"2024","unstructured":"Sizar O, Podder V, Talati R, Empagliflozin. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Vivek podder declares no relevant financial relationships with ineligible companies. Disclosure: Raja Talati declares no relevant financial relationships with ineligible companies; 2024."},{"issue":"7","key":"1895_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","volume":"16","author":"DL Eizirik","year":"2020","unstructured":"Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16(7):349\u201362.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1895_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/1871530321666210924124336","volume":"22","author":"G Lisco","year":"2022","unstructured":"Lisco G, Giagulli VA, De Pergola G, Guastamacchia E, Jirillo E, Triggiani V. Hyperglycemia-Induced immune system disorders in diabetes mellitus and the concept of hyperglycemic memory of innate immune cells: A perspective. Endocr Metab Immune Disord Drug Targets. 2022;22(4):367\u201370.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"4","key":"1895_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.7150\/ijms.23097","volume":"15","author":"YL Shih","year":"2018","unstructured":"Shih YL, Lu HF, Hsiao CW, Ho KT, Chen PC, Huang CN, et al. Distribution of cytotoxic T Lymphocyte-Associated Antigen-4 promoter polymorphisms in Taiwanese patients with type 2 diabetes mellitus. Int J Med Sci. 2018;15(4):395\u2013402.","journal-title":"Int J Med Sci"},{"issue":"3","key":"1895_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000356747","volume":"60","author":"BK Itariu","year":"2014","unstructured":"Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus - a mini-review. Gerontology. 2014;60(3):189\u201396.","journal-title":"Gerontology"},{"issue":"9","key":"1895_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/0895-4356(88)90096-0","volume":"41","author":"RE Stein","year":"1988","unstructured":"Stein RE, Jessop DJ. Thoughts on interdisciplinary research. J Clin Epidemiol. 1988;41(9):813\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1895_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41574-019-0286-3","volume":"16","author":"W Ying","year":"2020","unstructured":"Ying W, Fu W, Lee YS, Olefsky JM. The role of macrophages in obesity-associated islet inflammation and beta-cell abnormalities. Nat Rev Endocrinol. 2020;16(2):81\u201390.","journal-title":"Nat Rev Endocrinol"},{"key":"1895_CR28","first-page":"322","volume":"9","author":"N Saito","year":"2017","unstructured":"Saito N, Kimura S, Miyamoto T, Fukushima S, Amagasa M, Shimamoto Y, et al. Macrophage ubiquitin-specific protease 2 modifies insulin sensitivity in obese mice. Biochem Biophys Rep. 2017;9:322\u20139.","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"1895_CR29","doi-asserted-by":"publisher","first-page":"20240912","DOI":"10.1515\/med-2024-0912","volume":"19","author":"Z Ju","year":"2024","unstructured":"Ju Z, Cui F, Mao Z, Li Z, Yi X, Zhou J, et al. miR-335-3p improves type II diabetes mellitus by IGF-1 regulating macrophage polarization. Open Med (Wars). 2024;19(1):20240912.","journal-title":"Open Med (Wars)"},{"issue":"1","key":"1895_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1189\/jlb.0213075","volume":"95","author":"H Cucak","year":"2014","unstructured":"Cucak H, Grunnet LG, Rosendahl A. Accumulation of M1-like macrophages in type 2 diabetic Islets is followed by a systemic shift in macrophage polarization. J Leukoc Biol. 2014;95(1):149\u201360.","journal-title":"J Leukoc Biol"},{"key":"1895_CR31","doi-asserted-by":"publisher","first-page":"112802","DOI":"10.1016\/j.intimp.2024.112802","volume":"140","author":"J Wang","year":"2024","unstructured":"Wang J, Wang L, Han L, Han Y, Gu J, Chen Z. Formononetin attenuates hepatic injury in diabetic mice by regulating macrophage polarization through the PTP1B\/STAT6 axis. Int Immunopharmacol. 2024;140:112802.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1895_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13287-019-1338-2","volume":"10","author":"J Gao","year":"2019","unstructured":"Gao J, Cheng Y, Hao H, Yin Y, Xue J, Zhang Q, et al. Decitabine assists umbilical cord-derived mesenchymal stem cells in improving glucose homeostasis by modulating macrophage polarization in type 2 diabetic mice. Stem Cell Res Ther. 2019;10(1):259.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"1895_CR33","doi-asserted-by":"publisher","first-page":"11052","DOI":"10.1038\/s41598-017-11449-w","volume":"7","author":"M Fan","year":"2017","unstructured":"Fan M, Sun X, Xu N, Liao Z, Li Y, Wang J, et al. Integration of deep transcriptome and proteome analyses of Salicylic acid regulation high temperature stress in Ulva prolifera. Sci Rep. 2017;7(1):11052.","journal-title":"Sci Rep"},{"issue":"1","key":"1895_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12032-019-1326-5","volume":"37","author":"CE Perez-Juarez","year":"2019","unstructured":"Perez-Juarez CE, Arechavaleta-Velasco F, Zeferino-Toquero M, Alvarez-Arellano L, Estrada-Moscoso I, Diaz-Cueto L. Inhibition of PI3K\/AKT\/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors. Med Oncol. 2019;37(1):4.","journal-title":"Med Oncol"},{"issue":"1","key":"1895_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43556-024-00176-0","volume":"5","author":"S Zheng","year":"2024","unstructured":"Zheng S, He S, Liang Y, Tan Y, Liu Q, Liu T, et al. Understanding PI3K\/Akt\/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example. Mol Biomed. 2024;5(1):13.","journal-title":"Mol Biomed"},{"issue":"1","key":"1895_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13023-021-01929-8","volume":"16","author":"G Canaud","year":"2021","unstructured":"Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16(1):306.","journal-title":"Orphanet J Rare Dis"},{"key":"1895_CR37","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1038\/ncomms7118","volume":"6","author":"RL Chandler","year":"2015","unstructured":"Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun. 2015;6:6118.","journal-title":"Nat Commun"},{"issue":"5","key":"1895_CR38","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","volume":"174","author":"KT Kuo","year":"2009","unstructured":"Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597\u2013601.","journal-title":"Am J Pathol"},{"issue":"2","key":"1895_CR39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T Cell-Mediated immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"key":"1895_CR40","first-page":"3632576","volume":"2021","author":"Y Li","year":"2021","unstructured":"Li Y, Wang C, Gao Y, Zhou L. Identification and validation of PIK3CA as a marker associated with prognosis and immune infiltration in renal clear cell carcinoma. J Oncol. 2021;2021:3632576.","journal-title":"J Oncol"},{"key":"1895_CR41","doi-asserted-by":"crossref","unstructured":"Cheng YC, Chu LW, Chen JY, Hsieh SL, Chang YC, Dai ZK et al. Loganin attenuates high Glucose-Induced Schwann cells pyroptosis by inhibiting ROS generation and NLRP3 inflammasome activation. Cells. 2020;9(9).","DOI":"10.3390\/cells9091948"},{"key":"1895_CR42","doi-asserted-by":"publisher","first-page":"101563","DOI":"10.1016\/j.redox.2020.101563","volume":"34","author":"AM De Maranon","year":"2020","unstructured":"De Maranon AM, Iannantuoni F, Abad-Jimenez Z, Canet F, Diaz-Pozo P, Lopez-Domenech S, et al. Relationship between PMN-endothelium interactions, ROS production and Beclin-1 in type 2 diabetes. Redox Biol. 2020;34:101563.","journal-title":"Redox Biol"},{"key":"1895_CR43","doi-asserted-by":"publisher","first-page":"626390","DOI":"10.3389\/fendo.2021.626390","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, Wang S, Sun Z, Dong H, Yu H, Huang M, et al. Ferroptosis enhanced diabetic renal tubular injury via HIF-1alpha\/HO-1 pathway in db\/db mice. Front Endocrinol (Lausanne). 2021;12:626390.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1895_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.humimm.2021.03.004","volume":"82","author":"S Borzouei","year":"2021","unstructured":"Borzouei S, Moghimi H, Zamani A, Behzad M. Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. Hum Immunol. 2021;82(6):422\u20138.","journal-title":"Hum Immunol"},{"key":"1895_CR45","doi-asserted-by":"publisher","first-page":"105158","DOI":"10.1016\/j.neuint.2021.105158","volume":"150","author":"T Khan","year":"2021","unstructured":"Khan T, Khan S, Akhtar M, Ali J, Najmi AK. Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high Fructose diet induced hyperglycemic mice. Neurochem Int. 2021;150:105158.","journal-title":"Neurochem Int"},{"key":"1895_CR46","doi-asserted-by":"publisher","first-page":"9944880","DOI":"10.1155\/2021\/9944880","volume":"2021","author":"N Lee","year":"2021","unstructured":"Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-Stimulated macrophage via the IKK\/NF-kappaB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res. 2021;2021:9944880.","journal-title":"J Immunol Res"},{"key":"1895_CR47","doi-asserted-by":"publisher","first-page":"109506","DOI":"10.1016\/j.cellsig.2019.109506","volume":"68","author":"NA Das","year":"2020","unstructured":"Das NA, Carpenter AJ, Belenchia A, Aroor AR, Noda M, Siebenlist U, et al. Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. Cell Signal. 2020;68:109506.","journal-title":"Cell Signal"},{"issue":"4","key":"1895_CR48","first-page":"384","volume":"22","author":"Z Ashrafi Jigheh","year":"2019","unstructured":"Ashrafi Jigheh Z, Ghorbani Haghjo A, Argani H, Roshangar L, Rashtchizadeh N, Sanajou D, et al. Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis. Iran J Basic Med Sci. 2019;22(4):384\u201390.","journal-title":"Iran J Basic Med Sci"},{"key":"1895_CR49","doi-asserted-by":"publisher","first-page":"122026","DOI":"10.1016\/j.lfs.2023.122026","volume":"331","author":"Z Wang","year":"2023","unstructured":"Wang Z, Cui X, Yan W, Liu N, Shang J, Yi X, et al. Mollugin activates GLP-1R to improve cognitive dysfunction in type 2 diabetic mice. Life Sci. 2023;331:122026.","journal-title":"Life Sci"},{"issue":"1","key":"1895_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/kjm2.12625","volume":"39","author":"FT He","year":"2023","unstructured":"He FT, Fu XL, Li MH, Fu CY, Chen JZ. LncRNA SNHG1 targets miR-340-5p\/PIK3CA axis to regulate microvascular endothelial cell proliferation, migration, and angiogenesis in DR. Kaohsiung J Med Sci. 2023;39(1):16\u201325.","journal-title":"Kaohsiung J Med Sci"},{"issue":"4","key":"1895_CR51","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s00125-006-0522-y","volume":"50","author":"C D\u2019Alessandris","year":"2007","unstructured":"D\u2019Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia. 2007;50(4):840\u20139.","journal-title":"Diabetologia"},{"issue":"1","key":"1895_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jep.2012.06.050","volume":"143","author":"LY Wang","year":"2012","unstructured":"Wang LY, Wang Y, Xu DS, Ruan KF, Feng Y, Wang S. MDG-1, a polysaccharide from ophiopogon japonicus exerts hypoglycemic effects through the PI3K\/Akt pathway in a diabetic KKAy mouse model. J Ethnopharmacol. 2012;143(1):347\u201354.","journal-title":"J Ethnopharmacol"},{"key":"1895_CR53","doi-asserted-by":"crossref","unstructured":"Mihaljevic V, Zjalic M, Kizivat T, Omanovic Kolaric T, Smolic M, Rodak E et al. Molecular mechanisms linking empagliflozin to renal protection in the LLC-PK1 model of diabetic nephropathy. Biomedicines. 2022;10(11):2983.","DOI":"10.3390\/biomedicines10112983"},{"issue":"3","key":"1895_CR54","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7150\/ijbs.33007","volume":"16","author":"YH Lu","year":"2020","unstructured":"Lu YH, Chang YP, Li T, Han F, Li CJ, Li XY, et al. Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK\/AKT\/CREB signaling pathway in type 2 diabetic mice. Int J Biol Sci. 2020;16(3):529\u201342.","journal-title":"Int J Biol Sci"},{"key":"1895_CR55","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","volume":"94","author":"Z Meng","year":"2021","unstructured":"Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the ampk\/mtor\/autophagy pathway. Int Immunopharmacol. 2021;94:107492.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1895_CR56","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41419-022-04980-w","volume":"13","author":"W Wu","year":"2022","unstructured":"Wu W, Zhang Z, Jing D, Huang X, Ren D, Shao Z, et al. SGLT2 inhibitor activates the STING\/IRF3\/IFN-beta pathway and induces immune infiltration in osteosarcoma. Cell Death Dis. 2022;13(6):523.","journal-title":"Cell Death Dis"},{"key":"1895_CR57","doi-asserted-by":"crossref","unstructured":"Lee CT, Lin KD, Hsieh CF, Wang JY. SGLT2 inhibitor Canagliflozin alleviates high Glucose-Induced inflammatory toxicity in BV-2 microglia. Biomedicines. 2023;12(1):36.","DOI":"10.3390\/biomedicines12010036"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01895-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:36:45Z","timestamp":1757345805000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01895-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Heilongjiang Provincial Hospital deemed that this research is based on open-source data, so the need for ethics approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}